Literature DB >> 12964258

The natural history of carpal tunnel syndrome. A study of 20 hands evaluated 4 to 9 years after initial diagnosis.

L A Resende1, A Tahara, R G Fonseca, T Sardenberg.   

Abstract

Carpal tunnel syndrome (CTS) is the most frequent entrapment neuropathy. In the last decade several papers have been published on epidemiology, clinical aspects, diagnosis, and treatment, but little is known about its natural history. The objective of this work was to study the natural history of CTS syndrome. From 358 patients with clinical and conduction study diagnosis of CTS, 12 cases were identified that had refused surgical treatment, had not used anti-inflammatory medications, and had not undergone orthopaedic procedures, such as immobilization or anaesthetic infiltration. These 12 patients have 20 compromised hands which have been followed up for between 4 and 9 years. In all cases sensory and motor conduction studies were performed on the median nerve, at the beginning and end of follow-up period. Electrical improvement was marked in 5 hands and slight in 3; there was no significant change in 10, and deterioration in 2. As 8 hands (7 patients) showed improved clinical symptoms and conduction studies over several years, this brings the universally accepted procedure of surgical treatment into doubt.

Entities:  

Mesh:

Year:  2003        PMID: 12964258

Source DB:  PubMed          Journal:  Electromyogr Clin Neurophysiol        ISSN: 0301-150X


  10 in total

1.  Long-term symptomatic, functional, and work outcomes of carpal tunnel syndrome among construction workers.

Authors:  Bradley Evanoff; Bethany T Gardner; Jaime R Strickland; Skye Buckner-Petty; Alfred Franzblau; Ann Marie Dale
Journal:  Am J Ind Med       Date:  2016-02-23       Impact factor: 2.214

2.  Natural history and predictors of long-term pain and function among workers with hand symptoms.

Authors:  Alexis Descatha; Ann Marie Dale; Alfred Franzblau; Bradley Evanoff
Journal:  Arch Phys Med Rehabil       Date:  2013-02-14       Impact factor: 3.966

3.  Corticosteroid Injections for Carpal Tunnel Syndrome: Long-Term Follow-Up in a Population-Based Cohort.

Authors:  Stefanie Evers; Andrew J Bryan; Thomas L Sanders; Tina Gunderson; Russell Gelfman; Peter C Amadio
Journal:  Plast Reconstr Surg       Date:  2017-08       Impact factor: 4.730

Review 4.  Splinting for carpal tunnel syndrome.

Authors:  Matthew J Page; Nicola Massy-Westropp; Denise O'Connor; Veronica Pitt
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

5.  Role of Biomechanical Factors in Resolution of Carpal Tunnel Syndrome Among a Population of Workers.

Authors:  Amilcar Cardona; Matthew S Thiese; Jay Kapellusch; Andrew Merryweather; Eric Wood; Kurt T Hegmann
Journal:  J Occup Environ Med       Date:  2019-04       Impact factor: 2.162

6.  Current options for nonsurgical management of carpal tunnel syndrome.

Authors:  Hans Carlson; Agatha Colbert; Jennifer Frydl; Elizabeth Arnall; Molly Elliot; Nels Carlson
Journal:  Int J Clin Rheumtol       Date:  2010-02

7.  Outcomes and cost-effectiveness of carpal tunnel injections using sonographic needle guidance.

Authors:  Tony Makhlouf; N Suzanne Emil; Wilmer L Sibbitt; Roderick A Fields; Arthur D Bankhurst
Journal:  Clin Rheumatol       Date:  2013-11-26       Impact factor: 2.980

8.  Injection versus Decompression for Carpal Tunnel Syndrome-Pilot trial (INDICATE-P)-protocol for a randomised feasibility study.

Authors:  Will Mason; Daniel Ryan; Asif Khan; Hui-Ling Kerr; David Beard; Jonathan Cook; Ines Rombach; Cushla Cooper
Journal:  Pilot Feasibility Stud       Date:  2017-04-24

9.  Use of a decision aid did not decrease decisional conflict in patients with carpal tunnel syndrome.

Authors:  Hyun Sik Gong; Jin Woo Park; Young Ho Shin; Kahyun Kim; Kwan Jae Cho; Goo Hyun Baek
Journal:  BMC Musculoskelet Disord       Date:  2017-03-21       Impact factor: 2.362

Review 10.  Update on Efficacy of Conservative Treatments for Carpal Tunnel Syndrome.

Authors:  Teemu Karjalanen; Saara Raatikainen; Kati Jaatinen; Vieda Lusa
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.